# India Glioblastoma Market

> India Glioblastoma Market Research Report: Size, Share, Trend Analysis By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Immunotherapy), By Drug Type (Temozolomide, Bevacizumab, Carmustine, Nivolumab, Lomustine), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Specialty Pharmacy) andBy End Users (Hospitals, Clinical Research Organizations, Homecare Settings) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.22%
- **2024:** $ 170.03 Million
- **2025:** $ 180.61 Million
- **2035:** $ 330.08 Million
- **Key Players:** Bristol-Myers Squibb (US), Roche (CH), Merck & Co (US), Novartis (CH), Eli Lilly and Company (US), Amgen (US), AstraZeneca (GB), Regeneron Pharmaceuticals (US), Bayer (DE)

**Report ID:** MRFR/HC/48104-HCR · **Pages:** 200 · **Author:** Rahul Gotadki & Garvit Vyas · **Last Updated:** August 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/india-glioblastoma-market-49860

---

## Market Summary

## **India Glioblastoma Market Overview:**

As per MRFR analysis, the India Glioblastoma Market Size was estimated at 141.24 (USD Million) in 2023. The India Glioblastoma Market Industry is expected to grow from 149.46(USD Million) in 2024 to 712.6 (USD Million) by 2035. The India Glioblastoma Market CAGR (growth rate) is expected to be around 15.257% during the forecast period (2025 - 2035).

### **Key India Glioblastoma Market Trends Highlighted**

The India Glioblastoma Market is witnessing several important trends driven by rising awareness and advancements in healthcare. Increased funding for cancer research and the efforts of various government initiatives aim to improve diagnosis and treatment options for glioblastoma. The Indian government has been prioritizing cancer treatment through schemes such as the Ayushman Bharat, which provides health coverage to a significant portion of the population, thereby enhancing access to necessary therapies.

There is also a growing adoption of advanced technologies, such as precision medicine and targeted therapies, which offer better outcomes for patients with glioblastoma.This market still has opportunities to improve already existing methods of early diagnosis and treatment. The Indian pharmaceutical industry is increasingly shifting its focus towards the development of targeted therapies in the form of generic drugs and biosimilars, thus enhancing the affordability and accessibility of glioblastoma treatment. Partnerships between biotech companies and research organizations are also on the rise, which helps in fueling innovation and creating new therapies.

There is also a notable increase in the attention given to clinical trials focused on developing novel therapies for glioblastoma, indicating a growing trend toward personalized medicine.

Additionally, rising partnerships between private and public sectors in India are pushing the agenda for better cancer care. The participation of patient advocacy groups in awareness campaigns is creating a more informed patient population, which could lead to earlier diagnosis and treatment intervention. These trends highlight a focused effort to address glioblastoma effectively, underscoring both the challenges and advancements within the Indian healthcare landscape.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **India Glioblastoma Market Drivers**

### Rising Incidence of Glioblastoma in India

The India Glioblastoma Market Industry is experiencing growth due to the alarming rise in the incidence of glioblastoma. According to the National Cancer Registry Programme of India, there has been a substantial increase in brain tumor cases, with an estimate of over 30,000 new cases each year. This surge correlates with a broader increase in cancer cases overall, with female cancer patients in India rising by 4.7% and male cancer patients by 3.8% over the last decade.Organizations like the Indian Council of Medical Research are focusing on cancer research, leading to improved diagnosis and treatment options for glioblastoma.

As awareness and detection improve, more cases are being identified, driving the market for novel therapies and treatment protocols aimed at glioblastoma management.

### Advancements in Treatment Options

Technological advancements and the introduction of innovative treatment options are vital drivers for the India Glioblastoma Market Industry. The integration of technologies like personalized medicine and immunotherapy is gaining traction, with the Cancer Genome Atlas reporting that targeted therapies improve survival rates significantly. As pharmaceutical companies invest in Research and Development (R&D) for glioblastoma treatments, the number of clinical trials has surged, presenting new opportunities for patients.With increasing support from organizations like the Department of Biotechnology, these advancements are projected to enhance treatment efficacy, thereby expanding the market scope.

### Government Initiatives and Funding

Government initiatives aimed at cancer control are significantly influencing the India Glioblastoma Market Industry. The National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke seeks to reduce the cancer burden through increased funding and awareness campaigns. Reports indicate a projected allocation of significant funds by the Government of India towards cancer research and healthcare infrastructure, which is expected to facilitate early detection and increased access to advanced treatment options for glioblastoma patients.Such strategic investments are likely to bolster growth in the market as more patients receive timely and effective care.

## **India Glioblastoma Market Segment Insights:**

### **Glioblastoma Market Treatment Type Insights**

The India Glioblastoma Market, particularly under the Treatment Type segment, showcases a diverse range of therapeutic interventions aimed at tackling this aggressive form of brain cancer. The market is characterized by a comprehensive approach that includes Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, and Immunotherapy. Surgery, often considered the first line of defense, plays a pivotal role as it aims to remove as much of the tumor as possible, leading to improved patient outcomes and often serving as a critical factor for subsequent treatments.

Radiation Therapy utilized post-surgery, leverages high-energy particles to destroy remaining cancerous cells and is crucial in managing local disease control, particularly given the aggressive nature of glioblastoma. Chemotherapy, which employs potent drugs to target rapidly dividing cells, often works alongside surgeries and radiation to enhance the likelihood of treatment success, providing a systemic approach to combat potential metastasis. In recent years, Targeted Therapy has emerged as a significant player in the treatment landscape, focusing on specific genetic and molecular markers associated with glioblastoma, which allows for more personalized treatment regimens and better management of side effects.

Immunotherapy represents a progressive trend within the market, harnessing the body's immune system to identify and destroy cancer cells, bringing promising results and a new hope for patients who have limited options after conventional therapeutic strategies fail. The increasing prevalence of glioblastoma in India emphasizes the need for a diversified treatment approach, combining these therapies to maximize patient outcomes. Additionally, advancements in technology and Research and Development initiatives have resulted in innovative treatment options gaining traction in the market.

The potential for these treatment modalities to evolve with ongoing clinical trials and the incorporation of new findings will continue to shape India's Glioblastoma Market. As the healthcare system in India adopts more advanced and holistic treatment methodologies, a comprehensive understanding of these treatment types becomes vital for stakeholders aiming to improve patient care and outcomes within the realm of glioblastoma treatment.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Glioblastoma Market Drug Type Insights**

The Drug Type segment within the India Glioblastoma Market presents a diverse landscape, reflecting the complexities of treatment options available for this aggressive form of brain cancer. Temozolomide has established itself as a cornerstone in glioblastoma management due to its oral administration and effectiveness as a chemotherapeutic agent. Bevacizumab, known for its anti-angiogenic properties, plays a crucial role by targeting the tumor's blood supply, thus enhancing patient outcomes. Carmustine remains significant in clinical settings, often utilized in conjunction with other therapies to maximize efficacy.

Nivolumab, an immunotherapy agent, is gaining traction for its potential to activate the body’s immune response against cancer cells. Lomustine also contributes meaningfully, often seen in combination regimens, offering versatility in treatment protocols. The growth of these therapeutic options in India is driven by increasing incidences of glioblastoma, improved healthcare infrastructure, and greater awareness of treatment advancements.

Each drug brings distinct mechanisms of action and benefits, contributing to the overall efforts against glioblastoma and underscoring the importance of ongoing Research and Development within this market segment.As the India Glioblastoma Market evolves, these drug types will be pivotal in addressing the unmet needs of patients and healthcare providers alike.

### **Glioblastoma Market Distribution Channel Insights**

The Distribution Channel for the India Glioblastoma Market plays a crucial role in ensuring access to essential treatments for patients dealing with this aggressive form of brain cancer. The primary channels include Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Specialty Pharmacy, each serving its unique purpose in the healthcare ecosystem. Hospital pharmacies typically dominate the market as they cater to inpatients requiring immediate access to medications, making them vital in treatment frameworks.

Retail pharmacies also serve a significant number of outpatients, providing easy access to necessary medications in communities throughout India.The rise of online pharmacies has revolutionized the market by offering convenience and the ability for patients to obtain medications discreetly, especially in urban areas where internet penetration is high. Specialty pharmacies are particularly noteworthy due to their focus on high-cost, complex drugs that require special handling and administration, reflecting the growing need for specialized treatment pathways in the Indian healthcare landscape.

Overall, the diverse distribution channels highlight the adaptability and responsiveness of the healthcare sector in India to meet the increasing demand for glioblastoma treatments.

### **Glioblastoma Market End User Insights**

The End User segment of the India Glioblastoma Market plays a crucial role in addressing the healthcare needs of patients diagnosed with this aggressive form of brain cancer. Hospitals are significant contributors, providing specialized care, advanced surgical interventions, and comprehensive treatment options, which is essential in a country like India, where healthcare infrastructure is continually evolving.

Clinical Research Organizations serve as key players in conducting vital clinical trials and research, thus driving innovation in treatment modalities and therapeutic approaches for glioblastoma.Homecare settings have gained importance as they offer personalized care and comfort to patients, facilitating access to therapy in a familiar environment. This trend aligns with the growing emphasis on patient-centric care within India’s healthcare framework. The rising number of glioblastoma cases, coupled with increasing awareness and research breakthroughs, strengthens the demand across these end-user categories, leading to a dynamic transformation in how glioblastoma is treated and managed in India.

Market growth in these segments reflects broader trends in the healthcare system, driven by an aging population and increasing accessibility to healthcare facilities.

## **India Glioblastoma Market Key Players and Competitive Insights:**

The India Glioblastoma Market is characterized by a complex landscape where several pharmaceutical players are vying for dominance in the drug development and treatment space. This market has gained significant traction due to the increasing prevalence of glioblastoma, a severe form of brain cancer. Rising awareness about advanced treatment options and ongoing clinical trials further contribute to the competitive intensity within this sector. The market is defined not only by traditional treatment methods like surgery and radiotherapy but also by innovative therapies that target the underlying biology of the disease.

As research yields new insights into glioblastoma, companies are compelled to adapt their strategies, invest in research and development, and forge partnerships to enhance their market presence.Celgene has established a solid reputation within the India Glioblastoma Market, leveraging its significant strengths in research and development to create impactful therapeutic solutions. The company focuses on fostering innovative therapies that cater specifically to the needs of glioblastoma patients. Its commitment to advancing treatment options, coupled with extensive collaborations with various research institutions, enables Celgene to stay at the forefront of scientific discovery.

In India, Celgene has built strong relationships with healthcare providers and oncologists, which enhances its ability to deliver effective solutions tailored to the local market demands. The company’s proactive involvement in clinical trials and patient advocacy initiatives has further bolstered its position, allowing it to critically evaluate and optimize treatment approaches based on evolving patient needs.Novartis also plays a crucial role in the India Glioblastoma Market, recognized for its comprehensive portfolio of innovative therapies targeting cancer treatment.

The company offers key products that are pivotal in managing glioblastoma and has a solid market presence stemming from its strategic focus on oncology. Novartis has consistently emphasized the importance of research, yielding novel treatments that aim to improve patient outcomes. The company has engaged in strategic mergers and acquisitions that enhance its capacity for developing breakthrough therapies, thereby strengthening its foothold in the competitive landscape. In India, Novartis draws on its extensive network and partnerships with healthcare professionals to ensure that its cutting-edge therapies are accessible to patients.

This focus on collaboration, combined with its commitment to patient-centric solutions, positions Novartis as a formidable entity in the glioblastoma market, navigating challenges while contributing to advancements in cancer care.

### **Key Companies in the India Glioblastoma Market Include:**

### **India Glioblastoma Market Industry Developments**

The India Glioblastoma Market has recently experienced notable developments, particularly with regard to advancements in treatment options. Companies like Novartis and Merck and Co. have been focusing on innovative therapies, including targeted treatments, which have garnered increased interest from the healthcare community. In August 2023, Bristol-Myers Squibb expanded its glioblastoma program, aiming to investigate new immunotherapy combinations, which has further enhanced its presence in the market. Furthermore, significant mergers are reshaping the landscape; for instance, Eli Lilly announced its strategic acquisition of a biotech firm in July 2023 to bolster its oncology pipeline, aiming to develop more effective glioblastoma treatments.

The market valuation has been positively influenced by these developments as investment in Research and Development continues to rise. Over the past two years, the Indian government has also ramped up funding for cancer research initiatives, demonstrating its commitment to addressing high-incidence cancers like glioblastoma through both public and private sector partnerships. With companies like Pfizer and Roche focusing on collaborative clinical trials, the market is expected to see further innovations and advancements aimed at improving patient outcomes in India.

## **India Glioblastoma Market Segmentation Insights**

### **Glioblastoma Market Treatment Type****Outlook**

### **Glioblastoma Market Drug Type****Outlook**

### **Glioblastoma Market Distribution Channel****Outlook**

### **Glioblastoma Market End User****Outlook**

## Market Drivers

### Growing Awareness and Education

Growing awareness and education regarding glioblastoma among healthcare professionals and the general public are crucial drivers for the glioblastoma market in India. Increased knowledge about the symptoms, risk factors, and treatment options is likely to lead to earlier diagnosis and intervention. Educational initiatives, including workshops and seminars, are being organized to inform healthcare providers about the latest advancements in glioblastoma treatment. This heightened awareness can result in a more proactive approach to patient care, ultimately driving demand for innovative therapies. As patients become more informed about their options, they may seek advanced treatments, further stimulating the glioblastoma market. The ongoing efforts to enhance education and awareness are expected to have a lasting impact on market dynamics.

### Rising Incidence of Glioblastoma

The increasing incidence of glioblastoma in India is a primary driver for the glioblastoma market. Recent statistics indicate that the annual incidence rate of glioblastoma is approximately 3.2 cases per 100,000 individuals. This rising trend necessitates the development of effective treatment options, thereby stimulating market growth. As awareness of the disease grows, more patients are being diagnosed, leading to a higher demand for innovative therapies. The healthcare system is responding to this need by investing in advanced treatment modalities, which is likely to enhance the glioblastoma market. Furthermore, the aging population in India, which is more susceptible to various cancers, including glioblastoma, is expected to contribute to the increasing patient pool, further driving market dynamics.

### Government Initiatives and Support

Government initiatives aimed at cancer control and research funding are playing a pivotal role in shaping the glioblastoma market in India. The Indian government has launched various programs to enhance cancer care, including the National Cancer Control Program, which focuses on early detection and treatment. Increased funding for cancer research is likely to lead to the development of new therapies and treatment protocols for glioblastoma. Additionally, public awareness campaigns are being implemented to educate the population about the disease, which may result in earlier diagnoses and improved treatment outcomes. These initiatives not only support patients but also encourage pharmaceutical companies to invest in the glioblastoma market, fostering innovation and growth.

### Advancements in Diagnostic Technologies

Technological advancements in diagnostic tools are significantly impacting the glioblastoma market in India. Enhanced imaging techniques, such as MRI and PET scans, allow for earlier and more accurate detection of glioblastoma, which is crucial for effective treatment planning. The integration of artificial intelligence in imaging analysis is also emerging, potentially improving diagnostic accuracy and patient outcomes. As these technologies become more accessible, healthcare providers are likely to adopt them, leading to an increase in diagnosed cases. This, in turn, drives the demand for targeted therapies and innovative treatment options, thereby propelling the glioblastoma market forward. The ongoing research and development in this area suggest a promising future for diagnostic advancements, which could further influence market growth.

### Emergence of Innovative Treatment Modalities

The emergence of innovative treatment modalities, such as immunotherapy and personalized medicine, is transforming the glioblastoma market in India. These advanced therapies offer new hope for patients with glioblastoma, which has traditionally been challenging to treat. The introduction of CAR T-cell therapy and other immunotherapeutic approaches is gaining traction, potentially improving survival rates. As clinical trials yield promising results, healthcare providers are likely to adopt these therapies, leading to increased market demand. Furthermore, the collaboration between research institutions and pharmaceutical companies is expected to accelerate the development of novel treatment options, thereby enhancing the glioblastoma market. This trend indicates a shift towards more effective and tailored treatment strategies for patients.

## Future Outlook

The [Glioblastoma Market](https://www.marketresearchfuture.com/reports/glioblastoma-market-8307) in India is projected to grow at a 6.22% CAGR from 2025 to 2035, driven by advancements in treatment options and increasing patient awareness.

**New opportunities:**

- Development of personalized medicine solutions for glioblastoma patients. Expansion of telemedicine services for remote patient monitoring. Investment in AI-driven diagnostic tools for early detection of glioblastoma.

By 2035, the glioblastoma market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Treatment Type: Surgery (Largest) vs. Immunotherapy (Fastest-Growing)

In the treatment landscape for glioblastoma, Surgery remains the largest segment, capturing a significant market share due to its effectiveness in tumor removal. Following closely are Radiation Therapy and Chemotherapy, playing vital roles in post-surgical treatment protocols. Targeted Therapy is gaining traction, driven by advancements in personalized medicine, catering to specific tumor characteristics. Immunotherapy, although currently smaller, is rapidly evolving, supported by increasing clinical trials and research initiatives.

Growth in the Treatment Type segment is primarily fueled by technological advancements and a better understanding of glioblastoma's biological mechanisms. The rising incidence of glioblastoma, coupled with increased investment in research and development, is steering the market towards innovative treatment options. Emerging therapies such as Immunotherapy, supported by promising clinical outcomes, are contributing to a dynamic shift in treatment paradigms, ultimately driving the overall growth of the India glioblastoma market.

Surgery: Dominant vs. Immunotherapy: Emerging

Surgery is the cornerstone of glioblastoma treatment, widely recognized for its role in achieving initial tumor debulking. As the dominant treatment, it effectively reduces tumor burden, allowing for subsequent therapies to be more effective. However, emerging Immunotherapy is rapidly gaining attention for its potential to harness the body's immune system to combat cancer. This novel approach is characterized by its ability to achieve long-term remission in certain patient populations. The growing body of evidence supporting immunotherapeutic strategies is propelling its adoption in treatment protocols, marking it as a promising frontier in the fight against glioblastoma.

### By Drug Type: Temozolomide (Largest) vs. Nivolumab (Fastest-Growing)

In the India glioblastoma market, Temozolomide holds a dominating market share due to its established efficacy in treating glioblastoma patients. Other drugs like Bevacizumab and Carmustine contribute significantly but do not match the market presence of Temozolomide. Notably, Nivolumab is emerging with a promising share and is gaining traction among oncologists, leveraging endorsements from recent clinical trials and positive patient outcomes.

The growth trends in this segment showcase an increasing adoption of innovative therapies. Nivolumab, in particular, is on an upward trajectory owing to its immune checkpoint inhibitor mechanism, appealing to a segment of the market focused on personalized medicine. The evolving treatment landscape, driven by research developments and supportive healthcare policies, is likely to strengthen the performance of both established and emerging drug types in the forthcoming years.

Temozolomide (Dominant) vs. Nivolumab (Emerging)

Temozolomide stands as the dominant treatment option in the India glioblastoma market, primarily due to its longstanding effectiveness and physician familiarity. This drug has been the mainstay for treating both newly diagnosed and recurrent glioblastoma. Conversely, Nivolumab, an emerging player, utilizes a distinct mechanism that targets the immune system to combat tumor growth, representing a shift towards immunotherapy in cancer treatment. As clinical research continues to validate its potential, Nivolumab is expected to carve out a significant niche in the treatment paradigm, appealing particularly to patients looking for advanced therapeutic options. The contrasting profiles of these drugs illustrate a market in transition, balancing established protocols with innovative approaches.

### By Distribution Channel: Hospital Pharmacy (Largest) vs. Online Pharmacy (Fastest-Growing)

The distribution of glioblastoma treatment through various channels in the India glioblastoma market shows a diverse landscape. Hospital pharmacies hold the largest share due to their integration with patient care and treatment plans. Retail pharmacies and specialty pharmacies also contribute significantly, catering to localized markets and specific treatment regimens. Online pharmacies, while representing a smaller share currently, are gaining traction as patients and caregivers seek convenience and accessibility in medication procurement.

Growth trends indicate a shift towards online pharmacies as the fastest-growing segment, driven by increasing internet penetration and the rising preference for home-based healthcare solutions. The demand for specialized treatments and personalized medications in specialty pharmacies also continues to rise, reflecting a broader trend of personalized healthcare. Enhanced logistical capabilities and evolving consumer behavior play critical roles in shaping the future of distribution channels in this sector.

Hospital Pharmacy (Dominant) vs. Online Pharmacy (Emerging)

Hospital pharmacies serve as the dominant distribution channel for glioblastoma treatments, benefiting from direct access to healthcare providers and the integration of pharmaceutical care with patient management. Their established infrastructure ensures a streamlined process from prescription to administration, making them essential in acute care settings. Conversely, online pharmacies are emerging as a competitive force, appealing particularly to tech-savvy consumers and caregivers looking for convenience. The accessibility of medications through digital platforms, combined with doorstep delivery services, is attracting a growing patient base. This shift is indicative of a broader trend towards digitalization in healthcare, where the convenience and efficiency of online services are increasingly valued.

### By End User: Hospitals (Largest) vs. Clinical Research Organizations (Fastest-Growing)

In the India glioblastoma market, the distribution of end users reveals that hospitals hold the largest share, driven by their comprehensive treatment capabilities and advanced technological integration. Clinical research organizations are gaining traction as well, particularly due to increasing investments in clinical trials and innovative treatment methodologies. Homecare settings, although emerging, still represent a smaller segment primarily focused on palliative care and follow-up treatments.

Growth trends indicate that hospitals will continue to dominate the market, yet clinical research organizations are poised for rapid expansion, driven by heightened collaboration with pharmaceutical companies and an increase in the prevalence of glioblastoma. Homecare settings are gradually evolving, facilitated by advancements in telemedicine and a growing preference for at-home patient management, reflecting broader shifts in patient care approaches.

Hospitals (Dominant) vs. Clinical Research Organizations (Emerging)

Hospitals act as a dominant force in the India glioblastoma market, offering a wide range of specialized care and resources that enhance patient outcomes. With state-of-the-art facilities and multi-disciplinary teams, hospitals provide comprehensive treatment options, making them the primary choice for patients. In contrast, clinical research organizations represent an emerging segment, focusing on the development and execution of clinical trials that contribute to innovative treatment options. As they expand their services and partnerships with biotech firms, clinical research organizations are gaining importance in the landscape of glioblastoma care, capitalizing on the increasing need for effective therapies and potentially transforming patient care pathways.

## Competitive Benchmarking

The glioblastoma market exhibits a competitive landscape characterized by rapid innovation and strategic maneuvering among key players. Major companies such as Bristol-Myers Squibb (US), Roche (CH), and Novartis (CH) are actively engaged in enhancing their market presence through a combination of research and development, strategic partnerships, and regional expansions. Bristol-Myers Squibb (US) focuses on immunotherapy advancements, while Roche (CH) emphasizes personalized medicine approaches. Novartis (CH) is investing heavily in gene therapies, indicating a shift towards more targeted treatment modalities. Collectively, these strategies not only enhance their competitive positioning but also drive the overall growth of the market, as they respond to the increasing demand for effective glioblastoma treatments.In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and improve supply chain efficiency. This trend is particularly evident in the Indian market, where firms are optimizing their operations to cater to local needs. The competitive structure of the glioblastoma market appears moderately fragmented, with several players vying for market share. However, the influence of major companies remains substantial, as they leverage their resources and expertise to shape market dynamics.

In October  Roche (CH) announced a collaboration with a leading Indian biotech firm to develop a novel therapeutic approach for glioblastoma. This partnership is expected to enhance Roche's capabilities in localizing treatment options and accelerating the development of innovative therapies tailored to the Indian population. Such collaborations signify a strategic move towards integrating local insights into global research initiatives, potentially leading to more effective treatment solutions.

In September  Novartis (CH) launched a new clinical trial in India aimed at evaluating the efficacy of its latest gene therapy for glioblastoma. This initiative underscores Novartis's commitment to pioneering advanced treatment options and reflects a broader trend towards personalized medicine. The trial's outcomes could significantly influence treatment protocols and establish Novartis as a leader in innovative glioblastoma therapies.

In August  Bristol-Myers Squibb (US) expanded its oncology portfolio by acquiring a promising startup focused on immunotherapy for brain tumors. This acquisition not only diversifies Bristol-Myers Squibb's offerings but also enhances its research capabilities in the glioblastoma space. The strategic importance of this move lies in the potential to accelerate the development of breakthrough therapies that could redefine treatment standards.

As of November  the glioblastoma market is increasingly shaped by trends such as digitalization, sustainability, and the integration of artificial intelligence in drug development. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in navigating complex regulatory environments and enhancing research capabilities. Looking ahead, competitive differentiation is likely to evolve from traditional price-based strategies to a focus on innovation, technological advancements, and supply chain reliability. This shift may redefine how companies position themselves in the market, emphasizing the importance of developing cutting-edge therapies that meet the unique needs of patients.

## Recent News & Developments

The India Glioblastoma Market has recently experienced notable developments, particularly with regard to advancements in treatment options. Companies like Novartis and Merck and Co. have been focusing on innovative therapies, including targeted treatments, which have garnered increased interest from the healthcare community. In August 2023, Bristol-Myers Squibb expanded its glioblastoma program, aiming to investigate new immunotherapy combinations, which has further enhanced its presence in the market. Furthermore, significant mergers are reshaping the landscape; for instance, Eli Lilly announced its strategic acquisition of a biotech firm in July 2023 to bolster its oncology pipeline, aiming to develop more effective glioblastoma treatments.

The market valuation has been positively influenced by these developments as investment in Research and Development continues to rise. Over the past two years, the Indian government has also ramped up funding for cancer research initiatives, demonstrating its commitment to addressing high-incidence cancers like glioblastoma through both public and private sector partnerships. With companies like Pfizer and Roche focusing on collaborative clinical trials, the market is expected to see further innovations and advancements aimed at improving patient outcomes in India.

## Report Scope

| MARKET SIZE 2024 | 170.03(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 180.61(USD Million) |
| MARKET SIZE 2035 | 330.08(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.22% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Bristol-Myers Squibb (US), Roche (CH), Merck & Co (US), Novartis (CH), Eli Lilly and Company (US), Amgen (US), AstraZeneca (GB), Regeneron Pharmaceuticals (US), Bayer (DE) |
| Segments Covered | Treatment Type, Drug Type, Distribution Channel, End User |
| Key Market Opportunities | Advancements in targeted therapies and immunotherapies present growth opportunities in the glioblastoma market. |
| Key Market Dynamics | Rising demand for innovative therapies drives competition and investment in glioblastoma treatment advancements. |
| Countries Covered | India |

## Frequently Asked Questions

**Q: What is the projected market valuation for the India glioblastoma market by 2035?**
A: The projected market valuation for the India glioblastoma market is $330.08 Million by 2035.

**Q: What was the overall market valuation in 2024?**
A: The overall market valuation in 2024 was $170.03 Million.

**Q: What is the expected CAGR for the India glioblastoma market from 2025 to 2035?**
A: The expected CAGR for the India glioblastoma market during the forecast period 2025 - 2035 is 6.22%.

**Q: Which treatment type had the highest valuation in 2024?**
A: Chemotherapy had the highest valuation among treatment types, amounting to $51.01 Million to $100.02 Million in 2024.

**Q: What are the key players in the India glioblastoma market?**
A: Key players in the market include Bristol-Myers Squibb, Roche, Merck & Co, Novartis, Eli Lilly and Company, Amgen, AstraZeneca, Regeneron Pharmaceuticals, and Bayer.

**Q: Which drug type is expected to generate the highest revenue in the market?**
A: Temozolomide is expected to generate the highest revenue, with a valuation range of $60.0 Million to $120.0 Million.

**Q: What distribution channel is projected to have the highest market share?**
A: Specialty Pharmacy is projected to have the highest market share, with a valuation range of $80.03 Million to $140.08 Million.

**Q: What is the valuation range for hospitals as an end user in 2024?**
A: The valuation range for hospitals as an end user in 2024 was $85.0 Million to $165.0 Million.

**Q: How does the market for glioblastoma treatments appear to be evolving?**
A: The market for glioblastoma treatments appears to be evolving positively, with a projected increase in valuation from $170.03 Million in 2024 to $330.08 Million by 2035.

**Q: What is the valuation range for immunotherapy in 2024?**
A: The valuation range for immunotherapy in 2024 was $30.98 Million to $53.98 Million.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/india-glioblastoma-market-49860*